目的 探索構(gòu)建我國(guó)乳腺癌治療藥品的綜合評(píng)價(jià)指標(biāo)體系，從多維度評(píng)估藥品的綜合價(jià)值支持臨床合理用藥。方法 通過(guò)文獻(xiàn)綜述、專家咨詢收集證據(jù)，構(gòu)建評(píng)估框架體系，建立具體評(píng)估指標(biāo)，進(jìn)行指標(biāo)量化與賦權(quán)，并對(duì)最終構(gòu)建的指標(biāo)體系制定評(píng)分細(xì)則。結(jié)果 15名咨詢專家積極系數(shù)為1.00，權(quán)威系數(shù)為0.90，重要性和可行性協(xié)調(diào)系數(shù)分別為0.305和0.336。最終構(gòu)建的指標(biāo)體系包括6個(gè)維度下的14個(gè)二級(jí)指標(biāo)：安全性、經(jīng)濟(jì)性、適宜性、可及性各2個(gè)，有效性和創(chuàng)新性各3個(gè)。其中，有效性、安全性、經(jīng)濟(jì)性所占權(quán)重較高，分別賦分39分、19分、14分。結(jié)論 構(gòu)建的藥品綜合評(píng)價(jià)指標(biāo)體系符合乳腺癌藥品價(jià)值評(píng)估的需求，臨床可通過(guò)該體系對(duì)藥品評(píng)分比較，從而為臨床探索基于價(jià)值的藥品評(píng)分提供經(jīng)驗(yàn)參考。

Objective To establish a comprehensive evaluation index system for breast cancer treatment drugs in China, and to assess the comprehensive value of drugs from multiple dimensions to support clinical rational use. Methods Literature review and expert consultation were conducted to collect evidence that establishes a system of an evaluation framework and specific evaluation indices. Further modify the comprehensive assessment framework to determine the final assessment index system. Weigh each indicator by the appropriate algorithm and define the corresponding scoring rules. Results The positivity coefficient of 15 consulting experts is 1.00, the average authority is 0.90, and the opinion coordination coefficients of the importance and feasibility were 0.305 and 0.336. With this evaluation frame, there were six first-level indicators which include safety, efficacy, economy, innovation, appropriateness, and accessibility in this system, which consists with 14 second-level indicators. safety, economy, appropriateness, and accessibility each for 2, efficacy and innovation each for 3. Among them, effectiveness, safety and economy are given higher weights, with 39, 19 and 14 points respectively. Conclusion The comprehensive drug evaluation index system constructed in this study meets the needs of drug value assessment for breast cancer, which can provide experience reference for exploration of clinical value-based drug evaluation system.

R979.1